3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups

Natasha Szuber, Mythri Mudireddy, Maura Nicolosi, Domenico Penna, Rangit R. Vallapureddy, Terra L. Lasho, Christy Finke, Kebede Begna, Michelle A. Elliott, C. Christopher Hook, Alexandra P. Wolanskyj, Mrinal M Patnaik, Curtis A. Hanson, Rhett P. Ketterling, Shireen Sirhan, Animesh D Pardanani, Naseema Gangat, Lambert Busque, Ayalew Tefferi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: To document the Mayo Clinic decades-long experience with myeloproliferative neoplasms (MPNs) and provide mature risk-stratified survival data and disease complication estimates. Patients and Methods: All Mayo Clinic patients with World Health Organization–defined MPNs constituted the core study group and included those with polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Results: A total of 3023 consecutive patients (median age, 62 years; range, 18-96 years) were considered: 665 PV, 1076 ET, and 1282 PMF. From October 27, 1967, through December 29, 2017, 1631 deaths (54%), 183 leukemic transformations (6%), 244 fibrotic progressions (14%), and 516 thrombotic events (17%) were recorded. Median overall survival (OS) was 18 years for ET, 15 years for PV, and 4.4 years for PMF (P<.05 for all intergroup comparisons). Inferior survival was documented in patients with ET diagnosed more recently (post-1990) (P<.001), whereas survival data were time independent in PV and PMF. After conventional risk stratification, OS in low-risk ET and low-risk PV were superimposed (P=.89) but each differed significantly from that of age- and sex-matched controls (P<.001). Leukemia-free survival was similar for ET and PV (P=.22) and significantly worse with PMF (P<.001). Compared with ET, PV was associated with higher risk of fibrotic progression (P<.001). Thrombosis risk after diagnosis was highest in PV and lowest in PMF (P=.002 for PV vs ET; P=.56 for ET vs PMF; and P=.001 for PV vs PMF). Conclusion: This study provides the most mature survival and outcomes data in MPNs and highlights MPN subgroup risk categorization as key in appraising disease natural history. The OS was only marginally better in ET compared with PV, and PV displayed a higher risk of thrombosis and fibrotic progression.

Original languageEnglish (US)
JournalMayo Clinic proceedings
DOIs
StatePublished - Jan 1 2019

Fingerprint

Polycythemia Vera
Essential Thrombocythemia
Primary Myelofibrosis
Survival
Neoplasms
Thrombosis
Natural History
Leukemia

ASJC Scopus subject areas

  • Medicine(all)

Cite this

3023 Mayo Clinic Patients With Myeloproliferative Neoplasms : Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. / Szuber, Natasha; Mudireddy, Mythri; Nicolosi, Maura; Penna, Domenico; Vallapureddy, Rangit R.; Lasho, Terra L.; Finke, Christy; Begna, Kebede; Elliott, Michelle A.; Hook, C. Christopher; Wolanskyj, Alexandra P.; Patnaik, Mrinal M; Hanson, Curtis A.; Ketterling, Rhett P.; Sirhan, Shireen; Pardanani, Animesh D; Gangat, Naseema; Busque, Lambert; Tefferi, Ayalew.

In: Mayo Clinic proceedings, 01.01.2019.

Research output: Contribution to journalArticle

Szuber, N, Mudireddy, M, Nicolosi, M, Penna, D, Vallapureddy, RR, Lasho, TL, Finke, C, Begna, K, Elliott, MA, Hook, CC, Wolanskyj, AP, Patnaik, MM, Hanson, CA, Ketterling, RP, Sirhan, S, Pardanani, AD, Gangat, N, Busque, L & Tefferi, A 2019, '3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups', Mayo Clinic proceedings. https://doi.org/10.1016/j.mayocp.2018.08.022
Szuber, Natasha ; Mudireddy, Mythri ; Nicolosi, Maura ; Penna, Domenico ; Vallapureddy, Rangit R. ; Lasho, Terra L. ; Finke, Christy ; Begna, Kebede ; Elliott, Michelle A. ; Hook, C. Christopher ; Wolanskyj, Alexandra P. ; Patnaik, Mrinal M ; Hanson, Curtis A. ; Ketterling, Rhett P. ; Sirhan, Shireen ; Pardanani, Animesh D ; Gangat, Naseema ; Busque, Lambert ; Tefferi, Ayalew. / 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms : Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. In: Mayo Clinic proceedings. 2019.
@article{8a987d6ac0aa40d5b646109aca2a0da7,
title = "3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups",
abstract = "Objective: To document the Mayo Clinic decades-long experience with myeloproliferative neoplasms (MPNs) and provide mature risk-stratified survival data and disease complication estimates. Patients and Methods: All Mayo Clinic patients with World Health Organization–defined MPNs constituted the core study group and included those with polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Results: A total of 3023 consecutive patients (median age, 62 years; range, 18-96 years) were considered: 665 PV, 1076 ET, and 1282 PMF. From October 27, 1967, through December 29, 2017, 1631 deaths (54{\%}), 183 leukemic transformations (6{\%}), 244 fibrotic progressions (14{\%}), and 516 thrombotic events (17{\%}) were recorded. Median overall survival (OS) was 18 years for ET, 15 years for PV, and 4.4 years for PMF (P<.05 for all intergroup comparisons). Inferior survival was documented in patients with ET diagnosed more recently (post-1990) (P<.001), whereas survival data were time independent in PV and PMF. After conventional risk stratification, OS in low-risk ET and low-risk PV were superimposed (P=.89) but each differed significantly from that of age- and sex-matched controls (P<.001). Leukemia-free survival was similar for ET and PV (P=.22) and significantly worse with PMF (P<.001). Compared with ET, PV was associated with higher risk of fibrotic progression (P<.001). Thrombosis risk after diagnosis was highest in PV and lowest in PMF (P=.002 for PV vs ET; P=.56 for ET vs PMF; and P=.001 for PV vs PMF). Conclusion: This study provides the most mature survival and outcomes data in MPNs and highlights MPN subgroup risk categorization as key in appraising disease natural history. The OS was only marginally better in ET compared with PV, and PV displayed a higher risk of thrombosis and fibrotic progression.",
author = "Natasha Szuber and Mythri Mudireddy and Maura Nicolosi and Domenico Penna and Vallapureddy, {Rangit R.} and Lasho, {Terra L.} and Christy Finke and Kebede Begna and Elliott, {Michelle A.} and Hook, {C. Christopher} and Wolanskyj, {Alexandra P.} and Patnaik, {Mrinal M} and Hanson, {Curtis A.} and Ketterling, {Rhett P.} and Shireen Sirhan and Pardanani, {Animesh D} and Naseema Gangat and Lambert Busque and Ayalew Tefferi",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.mayocp.2018.08.022",
language = "English (US)",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",

}

TY - JOUR

T1 - 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms

T2 - Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups

AU - Szuber, Natasha

AU - Mudireddy, Mythri

AU - Nicolosi, Maura

AU - Penna, Domenico

AU - Vallapureddy, Rangit R.

AU - Lasho, Terra L.

AU - Finke, Christy

AU - Begna, Kebede

AU - Elliott, Michelle A.

AU - Hook, C. Christopher

AU - Wolanskyj, Alexandra P.

AU - Patnaik, Mrinal M

AU - Hanson, Curtis A.

AU - Ketterling, Rhett P.

AU - Sirhan, Shireen

AU - Pardanani, Animesh D

AU - Gangat, Naseema

AU - Busque, Lambert

AU - Tefferi, Ayalew

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: To document the Mayo Clinic decades-long experience with myeloproliferative neoplasms (MPNs) and provide mature risk-stratified survival data and disease complication estimates. Patients and Methods: All Mayo Clinic patients with World Health Organization–defined MPNs constituted the core study group and included those with polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Results: A total of 3023 consecutive patients (median age, 62 years; range, 18-96 years) were considered: 665 PV, 1076 ET, and 1282 PMF. From October 27, 1967, through December 29, 2017, 1631 deaths (54%), 183 leukemic transformations (6%), 244 fibrotic progressions (14%), and 516 thrombotic events (17%) were recorded. Median overall survival (OS) was 18 years for ET, 15 years for PV, and 4.4 years for PMF (P<.05 for all intergroup comparisons). Inferior survival was documented in patients with ET diagnosed more recently (post-1990) (P<.001), whereas survival data were time independent in PV and PMF. After conventional risk stratification, OS in low-risk ET and low-risk PV were superimposed (P=.89) but each differed significantly from that of age- and sex-matched controls (P<.001). Leukemia-free survival was similar for ET and PV (P=.22) and significantly worse with PMF (P<.001). Compared with ET, PV was associated with higher risk of fibrotic progression (P<.001). Thrombosis risk after diagnosis was highest in PV and lowest in PMF (P=.002 for PV vs ET; P=.56 for ET vs PMF; and P=.001 for PV vs PMF). Conclusion: This study provides the most mature survival and outcomes data in MPNs and highlights MPN subgroup risk categorization as key in appraising disease natural history. The OS was only marginally better in ET compared with PV, and PV displayed a higher risk of thrombosis and fibrotic progression.

AB - Objective: To document the Mayo Clinic decades-long experience with myeloproliferative neoplasms (MPNs) and provide mature risk-stratified survival data and disease complication estimates. Patients and Methods: All Mayo Clinic patients with World Health Organization–defined MPNs constituted the core study group and included those with polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Results: A total of 3023 consecutive patients (median age, 62 years; range, 18-96 years) were considered: 665 PV, 1076 ET, and 1282 PMF. From October 27, 1967, through December 29, 2017, 1631 deaths (54%), 183 leukemic transformations (6%), 244 fibrotic progressions (14%), and 516 thrombotic events (17%) were recorded. Median overall survival (OS) was 18 years for ET, 15 years for PV, and 4.4 years for PMF (P<.05 for all intergroup comparisons). Inferior survival was documented in patients with ET diagnosed more recently (post-1990) (P<.001), whereas survival data were time independent in PV and PMF. After conventional risk stratification, OS in low-risk ET and low-risk PV were superimposed (P=.89) but each differed significantly from that of age- and sex-matched controls (P<.001). Leukemia-free survival was similar for ET and PV (P=.22) and significantly worse with PMF (P<.001). Compared with ET, PV was associated with higher risk of fibrotic progression (P<.001). Thrombosis risk after diagnosis was highest in PV and lowest in PMF (P=.002 for PV vs ET; P=.56 for ET vs PMF; and P=.001 for PV vs PMF). Conclusion: This study provides the most mature survival and outcomes data in MPNs and highlights MPN subgroup risk categorization as key in appraising disease natural history. The OS was only marginally better in ET compared with PV, and PV displayed a higher risk of thrombosis and fibrotic progression.

UR - http://www.scopus.com/inward/record.url?scp=85061999166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061999166&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2018.08.022

DO - 10.1016/j.mayocp.2018.08.022

M3 - Article

C2 - 30824279

AN - SCOPUS:85061999166

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

ER -